Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer

Journal of Clinical Oncology

Volumn 27, Issue 34, 2009, Pages 5751-5756

  Hoskin, Peter J ^a   Robinson, Martin ^a   Slevin, Nicholas ^a   Morgan, David ^a   Harrington, Kevin ^a   Gaffney, Christopher ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DISEASE FREE SURVIVAL; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SKIN EXFOLIATION; THORAX PAIN; TREATMENT OUTCOME; BLOOD; DISEASE COURSE; HEAD AND NECK TUMOR; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EPOETIN ALFA; FATIGUE; FEMALE; HEAD AND NECK NEOPLASMS; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 73349123824     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.3693     Document Type: Article

References (17)

1. Dische S: Radiotherapy and anaemia: The clinical experience. Radiother Oncol 20:35-40, 1991
2. Harrison LB, Chadha M, Hill RJ, et al: Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 7:492-508, 2002
3. Witzig TE, Silberstein PT, Loprinzi CL, et al: Phase III randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23:2606-2617, 2005
4. Cella D, Zagari MJ, Vandoros C, et al: Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 21:366-373, 2003
5. Gabrilove JL, Cleeland CS, Livingston RB, et al: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875-2882, 2001
6. Littlewood JT, Bajetta E, Nortier JW, et al: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo controlled trial. J Clin Oncol 19:2865-2874, 2001
7. Glaspy J, Bukowski R, Steinberg D, et al: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15:1218-1234, 1997
8. Fallowfield L, Gagnon D, Zagari M, et al: Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm a quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer 87:1341-1353, 2002
9. Dammacco F, Castoldi G, Rödjer S: Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Hematol 113:172-179, 2001
10. Lavey RS, Dempsey W: Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys 27:1147-1152, 1993
11. Dusenbery KE, McGuire WA, Holt PJ, et al: Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 29:1079-1084, 1994
12. Vijayakumar S, Roach M, Wara W, et al: Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: Preliminary results of a randomized, open-labeled, phase II trial. Int J Radiat Oncol Biol Phys 26:721-729, 1993
13. Tsukuda M, Mochimatsu I, Nagahara T, et al: Clinical application of recombinant human erythropoietin for treatments in patients with head and neck cancer. Cancer Immunol Immunother 36:52-56, 1993
14. Henke M, Laszig R, Rübe C, et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362: 1255-1260, 2003
15. Overgaard J, Hoff C, Sand Hansen H, et al: Randomized study of the importance of Novel Erythropoiesis Stimulating Protein (Aranesp® ) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): The Danish Head and Neck Cancer Group DAHANCA 10 randomized trial. Eur J Cancer 5:7, 2007 (suppl)
16. Machtay M, Pajak TF, Suntharalingam M, et al: Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: A randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). Int J Radiat Oncol Biol Phys 69:1008-1017, 2007
17. Demetri GD, Kris M, Wade J, et al: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol 16:3412-3425, 1998